Claims
- 1. A compound according to the formula: ##STR6## wherein R=lower alkyl, cycloalkyl, cycloalkylloweralkyl, benzyl, or benzyl substituted by halogen, loweralkyl, loweralkoxy, or lower alkyl substituted by hydroxy, lower alkoxy, carbamoyl, N-loweralkylcarbamoyl, N,N-diloweralkylcarbamoyl and sulfamoyl;
- X,X.sub.1 =hydrogen and halogen;
- R.sub.1 =hydrogen, loweralkyl, unsaturated loweralkyl, loweralkoxyloweralkyl, or collectively with R.sub.2 is an alkylene chain forming an azetidine, pyrrolidine, piperidine, or hexahydroazepine ring, or collectively with R.sub.3 is a bond or an alkylene chain forming an azetidine, pyrrolidine, piperidine or a hexahydroazepine ring;
- R.sub.2 =hydrogen, loweralkyl or collectively with R.sub.3 is a bond or an alkylene chain to form a saturated carbocyclic ring of from 4 to 8 ring carbon atoms;
- R.sub.3,R.sub.4 =hydrogen, loweralkyl or collectively is an alkylene chain forming a saturated carbocyclic ring of from 4 to 6 ring carbon atoms;
- R.sub.5,R.sub.6 =hydrogen, C.sub.5 -C.sub.10 straight or branched chain alkyl, C.sub.3 -C.sub.6 cycloalkyl, cycloalkyl(lower)-alkyl, or loweralkyl substituted by phenyl which may be substituted by up to 3 substituents selected from hydroxy or methoxy groups;
- n=0, 1, 2;
- with the provisos that:
- (a) One of R.sub.5 and R.sub.6 must be hydrogen, but both cannot be hydrogen,
- (b) when R.sub.1 is unsaturated loweralkyl, the unsaturation cannot be alpha to the nitrogen atom,
- (c) when one of R.sub.5 or R.sub.6 is lower alkyl substituted by phenyl or substituted phenyl then said phenyl or substituted phenyl cannot be .alpha. to the nitrogen atom.
- or a pharmaceutically acceptable salt thereof.
- 2. A compound of claim 1 wherein R is loweralkyl.
- 3. A compound of claim 1 wherein X and X.sub.1 are both hydrogen.
- 4. A compound of claim 1 wherein R.sub.1,R.sub.2, R.sub.3 and R.sub.4 are hydrogen.
- 5. A compound of claim 1 wherein R is loweralkyl, R.sub.5 or R.sub.6 is hydrogen and X,X.sub.1,R.sub.1,R.sub.2, R.sub.3 and R.sub.4 are hydrogen.
- 6. A compound of claim 5 which is N-[2-((2-(3,4-dimethoxyphenyl)ethyl)amino)ethyl]-4-[(methylsulfonyl)amino]benzamide hydrochloride.
- 7. A compound of claim 5 which is N-[2-(heptylamino)-ethyl]-4-[(methylsulfonyl)amino]benzamide hydrochloride.
- 8. A compound of claim 5 which is N-(2[(cyclohexylmethyl) amino]ethyl]-4-[(methylsulfonyl)amino]benzamide.
- 9. The method of treating arrhythmias in a mammalian subject in need thereof comprising administering to said subject an antiarrhythmically effective dose of a compound according to the formula: ##STR7## wherein R=lower alkyl, cycloalkyl, cycloalkylloweralkyl, benzyl, or benzyl substituted by halogen, loweralkyl, loweralkoxy, or lower alkyl substituted by hydroxy, lower alkoxy, carbamoyl, N-loweralkylcarbamoyl, N,N-diloweralkylcarbamoyl and sulfamoyl:
- X,X.sub.1 =hydrogen and halogen;
- R.sub.1 =hydrogen, loweralkyl, unsaturated loweralkyl, loweralkoxyloweralkyl, or collectively with R.sub.2 is an alkylene chain forming an axetidine, pyrrolidine, piperidine, or hexahydroazepine ring, or collectively with R.sub.3 is a bond or an alkylene chain forming an azetidine, pyrrolidine, piperidine or a hexahydroazepine ring;
- R.sub.2 =hydrogen, loweralkyl or collectively with R.sub.3 is a bond or an alkylene chain to form a saturated carbocyclic ring of from 4 to 8 ring carbon atoms;
- R.sub.3,R.sub.4 =hydrogen, loweralkyl or collectively is an alkylene chain forming a saturated carbocyclic ring of from 4 to 6 ring carbon atoms;
- R.sub.5,R.sub.6 =hydrogen, C.sub.5 -C.sub.10 straight or branched chain alkyl, C.sub.3 -C.sub.6 cycloalkyl, cycloalkyl(lower)alkyl, or loweralkyl substituted by phenyl which may be substituted by up to 3 substituents selected from hydroxy or methoxy groups;
- n=0, 1, 2;
- with the provisos that:
- (a) One of R.sub.5 and R.sub.6 must be hydrogen, but both cannot be hydrogen,
- (b) when R.sub.1 is unsaturated loweralkyl, the unsaturation cannot be alpha to the nitrogen atom.
- or a pharmaceutically acceptable salt thereof;
- 10. A method of claim 9 wherein R is loweralkyl.
- 11. A method of claim 9 wherein X and X.sub.1 are both hydrogen.
- 12. A method of claim 9 wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are hydrogen.
- 13. A method of claim 9 wherein R is loweralkyl, R.sub.5 or R.sub.6 is hydrogen and X, X.sub.1, R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are hydrogen.
- 14. A method of claim 13 wherein the compound administered is N-[2-((2-(3,4-dimethoxyphenyl)ethyl)amino)ethyl]-4-[(methylsulfonyl)amino]benzamide hydrochloride.
- 15. A method of claim 13 wherein the compound administered is N-[2-(heptylamino)ethyl]-4-[(methylsulfonyl)amino]benzamide hydrochloride.
- 16. A method of claim 13 wherein the compound administered is 4-[(methylsulfonyl)-amino]-N-[2-[(phenylmethyl)amino]ethyl]-benzamide hydrochloride.
- 17. A method of claim 13 wherein the compound administered is N-[2-[(cyclohexyl-methyl)-amino]ethyl]-4-[(methylsulfonyl)-amino]benzamide.
Priority Claims (1)
Number |
Date |
Country |
Kind |
85101112.2 |
Feb 1985 |
EPX |
|
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a continuation-in-part of application Ser. No. 591,649 filed March 20, 1984, now U.S. Pat. No. 4,544,654.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4034106 |
Smith |
Jul 1977 |
|
4544654 |
Davey et al. |
Oct 1985 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
591649 |
Mar 1984 |
|